Home / Stocks / PCRX

Pacira BioSciences (PCRX, Pharmaceuticals) Stock Valuation & Fair Value Fairly valued

Pacira BioSciences (PCRX, Pharmaceuticals) trades at a blended P/E of 8.6, about 73% below its historical normal valuation, with a forward growth estimate of 13.0% and a PEG of 0.66. Analysts' one-year estimates have been hit 18% of the time. Priced at its historical normal P/E of 31.7 on the same blended earnings, the 2026-09-18 close of $24.69 corresponds to about $90.60 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
8.6
Normal P/E
31.7
PEG
0.66
Fwd growth
13.0%
Div yield
0.0%
RSI (14)
45.8
Neutral

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-07-31.

Blended P/E and rating by weekBlended P/E moved from 9.6 to 8.6 between 2026-07-31 and 2026-09-21, against a normal P/E of 31.7, with 0 rating changes over 18 recorded weeks.2026-07-31: P/E 9.6, Fairly valued (recalculated)2026-08-03: P/E 9.4, Fairly valued2026-08-07: P/E 9.4, Fairly valued (recalculated)2026-08-10: P/E 8.8, Fairly valued2026-08-14: P/E 8.8, Fairly valued (recalculated)2026-08-17: P/E 8.1, Fairly valued2026-08-21: P/E 8.1, Fairly valued (recalculated)2026-08-24: P/E 8.7, Fairly valued2026-08-27: P/E 8.7, Fairly valued (recalculated)2026-08-28: P/E 8.7, Fairly valued (recalculated)2026-08-30: P/E 8.7, Fairly valued (recalculated)2026-08-31: P/E 9.1, Fairly valued2026-09-05: P/E 9.1, Fairly valued (recalculated)2026-09-07: P/E 9.2, Fairly valued2026-09-12: P/E 9.2, Fairly valued (recalculated)2026-09-14: P/E 8.9, Fairly valued2026-09-19: P/E 8.9, Fairly valued (recalculated)2026-09-21: P/E 8.6, Fairly valued10.020.030.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 31.7
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 9.6-70%Fairly valued
2026-08-17P/E 8.1-74%Fairly valued
2026-09-21P/E 8.6-73%Fairly valued ← now

Frequently asked questions

Is Pacira BioSciences stock overvalued?

At a blended P/E of 8.6 versus its historical normal P/E of 31.7, Pacira BioSciences trades about 73% below its typical valuation, with a PEG of 0.66 on 13.0% forward growth. tickerseer currently rates it fairly valued.

What is Pacira BioSciences's fair value and PEG?

Pacira BioSciences trades at a blended P/E of 8.6 against a historical normal P/E of 31.7, a PEG of 0.66, and a forward growth estimate of 13.0%. Priced at its historical normal P/E of 31.7 on the same blended earnings, the 2026-09-18 close of $24.69 corresponds to about $90.60 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Pacira BioSciences changed?

tickerseer's rating has been fairly valued since 2026-07-31.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track PCRX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.